1.
Leukostasis as a result of rapidly progressive granulocytosis in a patient diagnosed with MDS/MPN-U.
Blood
; 134(23): 2117, 2019 12 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31805197
Assuntos
Medula Óssea , Neoplasias Hematológicas , Hidroxiureia/administração & dosagem , Leucostasia , Doenças Mieloproliferativas-Mielodisplásicas , Pirazóis/administração & dosagem , Idoso , Medula Óssea/metabolismo , Medula Óssea/patologia , Evolução Fatal , Neoplasias Hematológicas/tratamento farmacológico , Neoplasias Hematológicas/metabolismo , Neoplasias Hematológicas/patologia , Humanos , Leucostasia/tratamento farmacológico , Leucostasia/metabolismo , Leucostasia/patologia , Masculino , Doenças Mieloproliferativas-Mielodisplásicas/tratamento farmacológico , Doenças Mieloproliferativas-Mielodisplásicas/metabolismo , Doenças Mieloproliferativas-Mielodisplásicas/patologia , Nitrilas , Pirimidinas
2.
Leuk Res Rep
; 7: 6-10, 2017.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28066705
RESUMO
Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact on overall survival (p=<0.0001). Median OS of the comparator IC cohort was significantly inferior to that observed in the cohort treated with AZA in first line (p=0.0104). These results support the efficacy of AZA in AML in the elderly in any line of treatment.